Wellnex Life Q4 FY26: Cash Flow Positive Again, but Funding Remains Tight

Wellnex Life Limited has delivered its second consecutive quarter of positive net operating cash flow, providing further evidence that its operational turnaround is gaining traction.

The consumer health business generated $63,000 of net operating cash flow during the fourth quarter of FY26. That followed a positive $412,000 result in Q3 and took second-half operating cash flow to approximately $0.5 million.

Revenue, customer receipts and gross profit also improved during the quarter. However, investors should balance that progress against a relatively modest cash balance and the continuing importance of secured financing facilities.

All monetary figures in this article are in Australian dollars.

Wellnex Life's Q4 FY26 figures

Metric	Q4 FY26	Q3 FY26	Change
Brands revenue	$4.4 million	$3.5 million	25.7%
IP licensing revenue	$2.6 million	$1.6 million	62.5%
Total revenue	$7.0 million	$5.1 million	37.3%
Gross profit	$2.0 million	$1.5 million	33.3%
Customer receipts	$5.7 million	Not disclosed	Not disclosed
Net operating cash flow	$63,000	$412,000	Not disclosed
Quarter-end cash	$862,000	$217,000	$645,000 increase

The standout figure is the 37.3% quarter-on-quarter rise in revenue to $7.0 million. Growth came from both sides of the business, with brands revenue up 25.7% and intellectual property licensing revenue up 62.5%.

IP licensing allows another company to use Wellnex's intellectual property under an agreed commercial arrangement. This part of the business contributed $2.6 million of Q4 revenue, compared with $1.6 million in Q3.

Gross profit increased by 33.3% to $2.0 million. That was slightly slower than the rate of revenue growth, so investors will want to see whether future sales growth can translate into an equally strong improvement in gross profit.

Cash receipts show second-half improvement

Customer receipts reached $5.7 million during the quarter and $22.0 million across FY26. Second-half receipts totalled $12.4 million, which was 28% higher than in the first half.

Approximately $2.4 million of Q4 receipts came from Wellnex's licensing partnership with Haleon. The company also reported continued receipts from retail and pharmacy channel partners including Coles, Woolworths, Chemist Warehouse and major pharmacy wholesalers.

Cash receipts are not the same as reported revenue. Revenue is recognised under accounting rules, while receipts show the cash actually collected from customers during the period. For a smaller company with limited cash resources, the timing and quality of those receipts matter greatly.

This update builds on the improvement reported in Wellnex Life's Q3 cash-flow announcement.

Operating cash flow has turned around

Wellnex generated positive net operating cash flow of $63,000 in Q4, compared with $412,000 in Q3. Although the quarterly surplus reduced, this was still the second positive quarter in succession.

The wider half-year comparison is more encouraging. Operating cash flow was approximately $0.5 million positive in H2, against a $3.1 million outflow during H1. That represents an improvement of approximately $3.6 million half-on-half.

Higher receipts helped, but cost control was also important. Staff costs fell 21% quarter-on-quarter to $588,000, while advertising and marketing expenditure was held at $518,000.

Across the full financial year, however, net operating cash outflow was still $2.667 million. The second-half performance therefore marks a significant improvement rather than a completed turnaround.

Investors can also compare the latest figures with Wellnex Life's H1 FY26 results, when the company reported operating breakeven and an 8% increase in revenue.

Cash improved, but financing remains central

Wellnex ended June with $862,000 of cash and cash equivalents, up from $217,000 at the end of March.

That $645,000 increase was not driven solely by operating performance. The cash-flow statement shows $572,000 of net financing inflow during the quarter, comprising $3.497 million of borrowing proceeds, $2.884 million of repayments and $40,000 of equity transaction costs.

This is an important distinction. Positive operating cash flow is encouraging, but financing activity remained a major contributor to the higher closing cash balance.

At quarter-end, Wellnex reported total financing facilities of $11.870 million, with $9.391 million drawn and $2.479 million unused. Together with cash, the Appendix 4C showed total available funding of $3.341 million.

The facilities include:

• A $3.8 million secured revolving trade and debtor facility with Scottish Pacific, carrying interest at BBSY plus 6.8%.
• A secured Reach Wholesale loan facility of up to $5.325 million, carrying interest of 14% a year and expiring in August 2027.
• Director loans totalling $2.675 million, which were fully drawn at quarter-end.

BBSY is an Australian benchmark interest rate, meaning the cost of the Scottish Pacific facility can move as that benchmark changes.

The company said the repayment date for loans from former directors had been extended to the end of August 2026 at no additional cost. It also continues to assess opportunities to strengthen its balance sheet, although the form, timing and potential terms of any action were not disclosed.

Related-party payments

Wellnex disclosed $296,000 of payments to related parties and their associates during Q4. These covered directors' fees, executive remuneration and associated superannuation paid to directors and director-related entities in the ordinary course of business.

The disclosure is required under the Appendix 4C format, but it remains relevant when considering governance and cash allocation at a company with a limited cash balance.

What matters for Wellnex Life investors

The positive case is becoming clearer. Wellnex has now produced two consecutive quarters of positive operating cash flow, second-half receipts rose 28%, Q4 revenue increased 37.3%, and closing cash improved substantially from March.

The main caution is that liquidity remains tight in absolute terms. Quarter-end cash was only $862,000, while the business continued to use secured borrowings and recorded a $2.667 million operating cash outflow across FY26 as a whole.

The next test is whether Wellnex can maintain positive operating cash flow without relying on favourable collection timing or further significant financing inflows. Investors should also watch revenue quality, gross profit conversion, staff and marketing costs, and any balance-sheet strengthening measures.

For the primary figures and full Appendix 4C, see the original company announcement. Further company coverage is available on the Wellnex Life Limited share page.